5,6,3′,4′-Tetrahydroxy-7-methoxyflavone as a Novel Potential Proteasome Inhibitor

Abstract

Proteasome inhibition is one of the new pharmaceutical approaches to study antitumor activity. Although the active components are not yet identified for either treating or preventing cancer, the low toxicity plant Anisomeles ovata R. Br. has been used in traditional herbal medicine for more than 1000 years. In this study, the methanol extract from Anisomeles ovata showed potent inhibition of proteasome activity. Twenty compounds, two macrocycylic diterpenoids, six aromatics, seven flavonoids, and five phenylethanoids were isolated from Fang Feng Cao the dried aerial parts of A. ovata. Their structures have been established on the basis of spectral evidence. Using a proteolysis assay for inhibition of 26S proteasome from pig red blood cells, we found that 5,6,3′,4′-tetrahydroxy-7-methoxyflavone inhibited 90.5 %, 85.4 % and 73.1 % the chymotrypsin-like, caspase-like and trypsin-like activities of 26S proteasome with IC₅₀ values of 14.0, 5.4 and 24.1 µM, respectively, when Suc-LLVY‐AMC, Z‐LLE‐AMC and Ac-RLR‐AMC were used as substrates. 5,6,3′,4′-Tetrahydroxy-7-methoxyflavone had a higher inhibitory at 15 minutes. A combination of 5,6,3′,4′-tetrahydroxy-7-methoxyflavone and 5,6,4′-trihydroxy-7,3′-dimethoxyflavone increased the inhibition ability on 26S enzymatic activity. This combination appears to be a potentially attractive chemotherapy approach. We have found that 5,6,3′,4′-tetrahydroxy-7-methoxyflavone has the highest inhibitory effects on 26S proteasome activities when compared to the other 11 flavonoids. These results suggest that both the 6-hydroxy and 7-methoxy positions of the flavone may play an important role in targeting 26S proteasome activity.

5,6,3′,4′‐tetrahydroxy‐7‐methoxyflavone - MG132 - Anisomeles ovata R. Br. - Labiatae - 26S proteasome - 5,6,4′‐trihydroxy‐7,3′‐dimethoxyflavone - proteasome inhibitor

References

• 1 Glickman M H, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.  Physiol Rev. 2002;  82 373-428
• 2 Peters J M, Franke W W, Kleinschmidt J A. Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm.  J Biol Chem. 1994;  269 7709-7718
• 3 Groll M, Koguchi Y, Huber R, Kohno J. Crystal structure of the 20 S proteasome : TMC-95A complex: a non-covalent proteasome inhibitor.  J Mol Biol. 2001;  311 543-548
• 4 Marfella R, D'Amico M, Esposito K, Baldi A, Di Filippo C, Siniscalchi M, Sasso F C, Portoghese M, Cirillo F, Cacciapuoti F, Carbonara O, Crescenzi B, Baldi F, Ceriello A, Nicoletti G F, D'Andrea F, Verza M, Coppola L, Rossi F, Giugliano D. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment.  Diabetes. 2006;  55 622-632
• 5 Ishibashi Y, Hanyu N, Suzuki Y, Yanai S, Tashiro K, Usuba T, Iwabuchi S, Takahashi T, Takada K, Ohkawa K, Urashima M, Yanaga K. Quantitative analysis of free ubiquitin and multi-ubiquitin chain in colorectal cancer.  Cancer Lett. 2004;  211 111-117
• 6 Kumatori A, Tanaka K, Inamura N, Sone S, Ogura T, Matsumoto T, Tachikawa T, Shin S, Ichihara A. Abnormally high expression of proteasomes in human leukemic cells.  Proc Natl Acad Sci USA. 1990;  87 7071-7075
• 7 Deng S, Zhou H, Xiong R, Lu Y, Yan D, Xing T, Dong L, Tang E, Yang H. Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics.  Breast Cancer Res Treat. 2007;  104 21-30
• 8 Afjehi-Sadat L, Gruber-Olipitz M, Felizardo M, Slavc I, Lubec G. Expression of proteasomal proteins in ten different tumor cell lines.  Amino Acids. 2004;  27 129-140
• 9 Kisselev A F, Goldberg A L. Proteasome inhibitors: from research tools to drug candidates.  Chem Biol. 2001;  8 739-758
• 10 Adams J. The development of proteasome inhibitors as anticancer drugs.  Cancer Cell. 2004;  5 417-421
• 11 Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino M A, Anderson K C. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.  Blood. 2008;  111 1654-1664
• 12 Aghajanian C, Soignet S, Dizon D S, Pien C S, Adams J, Elliott P J, Sabbatini P, Miller V, Hensley M L, Pezzulli S, Canales C, Daud A, Spriggs D R. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.  Clin Cancer Res. 2002;  8 2505-2511
• 13 Hofmeister C C, Richardson P, Zimmerman T, Spear M A, Palladino M A, Longenecker A M, Cropp G F, Lloyd G K, Hannah A L, Anderson K. Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM).  J Clin Oncol. 2009;  27 8505
• 14 Chang T L, Ding H Y, Kao Y W. The role of ginsenoside Rd in inhibiting of 26S proteasome activity.  J Agric Food Chem. 2008;  56 12011-12015
• 15 Chiangsu New Medical College .Dictionary of Chinese Materia Medica. Shanghai; Shanghai Scientific and Technological 1981: 979-980
• 16 Rao L J M, Kumari G N K, Rao N S P. Terpenoids and steroids from Anisomeles ovate.  J Nat Prod. 1984;  47 1052
• 17 Arisawa M, Nimura M, Ikeda A, Hayashi T, Morita N, Momose Y, Takeda R, Nakanishi S. Biologically active macrocyclic diterpenoids from chinese drug “fáng féng cáo” I. Isolation and structure 1.  Planta Med. 1986;  52 38-41
• 18 Arisawa M, Nimura M, Fujita A, Hayashi T, Morita N, Koshimura S. Biological active macrocyclic diterpenoids from Chinese drug “Fáng Féng Cáo” II1. Derivatives of ovatodiolids and their cytotoxity 2.  Planta Med. 1986;  56 297-299
• 19 Manchand P S, Blount J F. Stereostructures of the macrocyclic diterpenoids ovatodiolide and isoovatodiolide.  J Org Chem. 1977;  42 3824-3828
• 20 Rao L J M, Kumari G N K, Rao N S P. 5,6-Dimethoxy-7,3′,4′-trihydroxyflavone from Anisomeles ovata.  Phytochemistry. 1983;  22 1522
• 21 Rao L J M, Kumari G N K, Rao N S P. 6-Methoxyflavone from Anisomeles ovata.  J Nat Prod. 1983;  46 595
• 22 Rao L J M, Kumari G N K, Rao N S P. Anisofolin-A, a new acylated flavone glucoside from Anisomeles ovata R. Br.  Heterocycles. 1982;  19 1655-1661
• 23 Rao L J M, Kumari G N K, Rao N S P. Two further acylated flavone glucosides from Anisomeles ovata.  Phytochemistry. 1983;  22 1058-1060
• 24 Rao L J M, Kumari G N K, Rao N S P. Flavonoid glycosides from Anisomeles ovata.  J Nat Prod. 1985;  48 150-151
• 25 Sakushima A, Coskun M, Maoka T. Hydroxybenzoic acid from Boreava orientalis.  Phytochemistry. 1995;  40 257-261
• 26 Ding H Y, Lin H C, Teng C M, Wu Y C. Phytochemical and pharmacological studies on Chinese Paeonia species.  J Chin Chem Soc. 2000;  47 381-388
• 27 Maldonado E, Ortega A. Neo-clerodane diterpenes from Salvia thymoides.  Phytochemistry. 1997;  46 1249-1254
• 28 Mitsuo M, Masayoshi H. Antimutagenic activity of flavonoids from Chrysanthemum morifolium.  Biosci Biotechnol Biochem. 2003;  67 2091-2099
• 29 Bisio A, Romussi G, Ciarallo G, De Tommasi N. Flavonoide und Triterpenoide aus Salvia blepharophylla Brandegee ex Epling.  Pharmazie. 1997;  52 330-331
• 30 Taguchi H. Studies on the constituents of Vitex cannabifolia.  Chem Pharm Bull. 1976;  24 1668-1670
• 31 Zhang H L, Nagatsu A, Okuyama H, Mizukami H, Sakakibara J. Glycosides from cotton oil cake.  Phytochemistry. 1998;  48 665-668
• 32 Goetz G, Fkyerat A, Metais N, Kunz M, Tabacchi R, Pezet R, Pont V. Resistance factors to grey mould in grape berries: identification of some phenolics inhibitors of Boteytis cinerea stilbene oxidase.  Phytochemistry. 1999;  52 759-767
• 33 Damtoft S, Jensen S R. Three phenylethanoid glucosides of unusual structure from Chirita sinensis (Gesneriaceae).  Phytochemistry. 1994;  37 441-443
• 34 Sasaki H, Nishimura H, Chin M, Mitsuhashi H. Hydroxycinnamic acid esters of phenethylalcohol glycosides from Rehmannia glutinosa var. purpurea.  Phytochemistry. 1989;  28 875-879
• 35 Venturella P, Bellino A, Marino M L. Three acylated flavone glycosides from Sideritis syriaca.  Phytochemistry. 1995;  38 527-530
• 36 Zimin L, Zhongjian J. Phenylpropanoid and iridoid glycosides from Pedicularis striata.  Phytochemistry. 1991;  30 1341-1344
• 37 Sakar M K, Petereit F, Naharstedt A. Two phlorogyucinol glucosides, flavane gallates and flavonol glycosides from Sedum sediforme flowers.  Phytochemistry. 1993;  33 171-174
• 38 Miyaichi Y, Kizu H, Tomimori T, Lin C. Studies on the constituents of the aerial parts of Scutellaria indica L.  Chem Pharm Bull. 1989;  37 794-797
• 39 He Z D, Ueda S, Inoue K, Akaji M, Fujita T, Yang C R. Secoiridoid glucosides from Fraxinus malacophylla.  Phytochemistry. 1993;  35 177-181
• 40 Liu C W, Li X, Thompson D, Wooding K, Chang T L, Tang Z, Yu H, Thomas P J, DeMartino G N. ATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasome.  Mol Cell. 2006;  24 39-50
• 41 Seo J M, Kang H M, Son K H, Kim J H, Lee C W, Kim H M, Chang S I, Kwon B M. Antitumor activity of flavones isolated from Artemisia argyi.  Planta Med. 2003;  69 218-222
• 42 Chen D, Daniel K G, Chen M S, Kuhn D J, Landis-Piwowar K R, Dou Q P. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells.  Biochem Pharmacol. 2005;  69 1421-1432
• 43 Kisselev A F, Callard A, Goldberg A L. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate.  J Biol Chem. 2006;  281 8582-8590
• 44 Chen D, Chen M S, Cui Q C, Yang H, Dou Q P. Structure-proteasome-inhibitory activity relationships of dietary flavonoids in human cancer cells.  Front Biosci. 2007;  12 1935-1945